Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 May 1;101(9):1835–1842. doi: 10.1172/JCI1268

Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.

O Asai 1, D L Longo 1, Z G Tian 1, R L Hornung 1, D D Taub 1, F W Ruscetti 1, W J Murphy 1
PMCID: PMC508768  PMID: 9576746

Abstract

Bone marrow transplantation (BMT) is currently used for the treatment of a variety of neoplastic diseases. However, significant obstacles limiting the efficacy of allogeneic BMT are the occurrence of graft-versus-host disease (GvHD) and tumor relapse. Natural killer (NK) cells exert a variety of immunologic and homoeostatic functions. We examined whether adoptive transfer of activated NK cells of donor type would prevent GvHD after allogeneic BMT in mice. Lethally irradiated C57BL/6 (H-2(b)) mice, were transplanted with MHC incompatible BALB/c (H-2(d)) bone marrow cells and spleen cells and rapidly succumbed to acute GvHD. In contrast, mice that also received activated NK cells of donor type exhibited significant increases in survival. In determining the mechanism by which the NK cells prevented GvHD, mice were concurrently treated with a neutralizing antibodies to the immunosuppressive cytokine TGFbeta. Anti-TGFbeta completely abrogated the protective effects of the activated donor NK cells indicating that TGFbeta plays an important role in the prevention of GvHD by NK cells. We then examined whether activated NK cells of donor type after allogeneic BMT would induce graft-versus-tumor (GvT) effects without GvHD in mice bearing a murine colon adenocarcinoma (MCA-38). 10 d after receiving the tumor, in which the mice had demonstrable lung metastases, recipients received an allogeneic BMT with or without activated NK cells. Administration of activated NK cells resulted in significant GvT effects after allogeneic BMT as evidenced by increases in median survival and fewer lung metastasis. No evidence of GVHD was detected compared with recipients receiving spleen cells alone which also developed fewer lung metastases but in which all had succumbed to GVHD. Thus, our findings suggest that adoptive immunotherapy using activated donor NK cells combined with allogeneic BMT inhibits GvHD and promotes GvT in advanced tumor-bearing mice. These results also suggest that GvT and GvHD can be dissociable phenomena.

Full Text

The Full Text of this article is available as a PDF (381.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armitage J. O. Bone marrow transplantation. N Engl J Med. 1994 Mar 24;330(12):827–838. doi: 10.1056/NEJM199403243301206. [DOI] [PubMed] [Google Scholar]
  2. Bortin M. M., Horowitz M. M., Rimm A. A. Increasing utilization of allogeneic bone marrow transplantation. Results of the 1988-1990 survey. Ann Intern Med. 1992 Mar 15;116(6):505–512. doi: 10.7326/0003-4819-116-6-505. [DOI] [PubMed] [Google Scholar]
  3. Dasch J. R., Pace D. R., Waegell W., Inenaga D., Ellingsworth L. Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. J Immunol. 1989 Mar 1;142(5):1536–1541. [PubMed] [Google Scholar]
  4. Favrot M. C., Floret D., Negrier S., Cochat P., Bouffet E., Zhou D. C., Franks C. R., Bijman T., Brunat-Mentigny M., Philip I. Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation. Bone Marrow Transplant. 1989 Sep;4(5):499–503. [PubMed] [Google Scholar]
  5. Ferrara J. L., Deeg H. J. Graft-versus-host disease. N Engl J Med. 1991 Mar 7;324(10):667–674. doi: 10.1056/NEJM199103073241005. [DOI] [PubMed] [Google Scholar]
  6. Ghayur T., Seemayer T. A., Lapp W. S. Prevention of murine graft-versus-host disease by inducing and eliminating ASGM1+ cells of donor origin. Transplantation. 1988 Mar;45(3):586–590. doi: 10.1097/00007890-198803000-00017. [DOI] [PubMed] [Google Scholar]
  7. Glass B., Uharek L., Zeis M., Loeffler H., Mueller-Ruchholtz W., Gassmann W. Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells. Br J Haematol. 1996 May;93(2):412–420. doi: 10.1046/j.1365-2141.1996.4941035.x. [DOI] [PubMed] [Google Scholar]
  8. Goldman J. M., Gale R. P., Horowitz M. M., Biggs J. C., Champlin R. E., Gluckman E., Hoffmann R. G., Jacobsen S. J., Marmont A. M., McGlave P. B. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med. 1988 Jun;108(6):806–814. doi: 10.7326/0003-4819-108-6-806. [DOI] [PubMed] [Google Scholar]
  9. Habu S., Fukui H., Shimamura K., Kasai M., Nagai Y., Okumura K., Tamaoki N. In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J Immunol. 1981 Jul;127(1):34–38. [PubMed] [Google Scholar]
  10. Levitt L. J., Nagler A., Lee F., Abrams J., Shatsky M., Thompson D. Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor. J Clin Invest. 1991 Jul;88(1):67–75. doi: 10.1172/JCI115306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Marmont A. M., Horowitz M. M., Gale R. P., Sobocinski K., Ash R. C., van Bekkum D. W., Champlin R. E., Dicke K. A., Goldman J. M., Good R. A. T-cell depletion of HLA-identical transplants in leukemia. Blood. 1991 Oct 15;78(8):2120–2130. [PubMed] [Google Scholar]
  12. Mowat A. M. Antibodies to IFN-gamma prevent immunologically mediated intestinal damage in murine graft-versus-host reaction. Immunology. 1989 Sep;68(1):18–23. [PMC free article] [PubMed] [Google Scholar]
  13. Murphy W. J., Bennett M., Kumar V., Longo D. L. Donor-type activated natural killer cells promote marrow engraftment and B cell development during allogeneic bone marrow transplantation. J Immunol. 1992 May 1;148(9):2953–2960. [PubMed] [Google Scholar]
  14. Murphy W. J., Keller J. R., Harrison C. L., Young H. A., Longo D. L. Interleukin-2-activated natural killer cells can support hematopoiesis in vitro and promote marrow engraftment in vivo. Blood. 1992 Aug 1;80(3):670–677. [PubMed] [Google Scholar]
  15. Murphy W. J., Reynolds C. W., Tiberghien P., Longo D. L. Natural killer cells and bone marrow transplantation. J Natl Cancer Inst. 1993 Sep 15;85(18):1475–1482. doi: 10.1093/jnci/85.18.1475. [DOI] [PubMed] [Google Scholar]
  16. Ruscetti F. W., Palladino M. A. Transforming growth factor-beta and the immune system. Prog Growth Factor Res. 1991;3(2):159–175. doi: 10.1016/s0955-2235(05)80006-7. [DOI] [PubMed] [Google Scholar]
  17. Storb R. Bone marrow transplantation. Transplant Proc. 1995 Oct;27(5):2649–2652. [PubMed] [Google Scholar]
  18. Sykes M., Abraham V. S. The mechanism of IL-2-mediated protection against GVHD in mice. II. Protection occurs independently of NK/LAK cells. Transplantation. 1992 May;53(5):1063–1070. doi: 10.1097/00007890-199205000-00018. [DOI] [PubMed] [Google Scholar]
  19. Sykes M., Pearson D. A., Szot G. L. IL-2-induced GVHD protection is not inhibited by cyclosporine and is maximal when IL-2 is given over a 25 h period beginning on the day following bone marrow transplantation. Bone Marrow Transplant. 1995 Mar;15(3):395–399. [PubMed] [Google Scholar]
  20. Sykes M., Romick M. L., Sachs D. H. Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells. Proc Natl Acad Sci U S A. 1990 Aug;87(15):5633–5637. doi: 10.1073/pnas.87.15.5633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Sykes M., Szot G. L., Nguyen P. L., Pearson D. A. Interleukin-12 inhibits murine graft-versus-host disease. Blood. 1995 Sep 15;86(6):2429–2438. [PubMed] [Google Scholar]
  22. Trinchieri G. Biology of natural killer cells. Adv Immunol. 1989;47:187–376. doi: 10.1016/S0065-2776(08)60664-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Yamamoto H., Hirayama M., Genyea C., Kaplan J. TGF-beta mediates natural suppressor activity of IL-2-activated lymphocytes. J Immunol. 1994 Apr 15;152(8):3842–3847. [PubMed] [Google Scholar]
  24. Zeis M., Uharek L., Glass B., Gaska T., Steinmann J., Gassmann W., Löffler H., Müller-Ruchholtz W. Allogeneic NK cells as potent antileukemic effector cells after allogeneic bone marrow transplantation in mice. Transplantation. 1995 Jun 27;59(12):1734–1736. doi: 10.1097/00007890-199506270-00016. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES